Sequential plasma samples from 30 patients showing clinical signs of hypersensitivity to Althesin were investigated to determine if a specific immune response to the drug was present (as measured by classical complement pathway activation) or if a non-antibody-dependent alternative complement pathway activation was taking place. The patients were classified as those reacting on first exposure to Althesin and those who reacted adversely only on a second exposure. The alternative complement pathway, but not the classical pathway, was activated in five of the 13 first-time reactors, while in the remaining eight no complement activation was detected. In contrast, classical complement pathway activation was demonstrated in the blood samples of all 17 patients reacting on repeat exposure. Severe reactions occurred in nine of the 17 previously exposed patients compared with only one of the 13 reacting on first exposure to Althesin.
The reported frequency of hypersensitivity reactions to the i.v. anaesthetic agent Althesin (alphaxalone/alphadolonc acetate in Cremophor EL) has varied from 1 in 930 (Evans and Keogh, 1977) to 1 in 433 (Beamish, 1979) and is considerably greater than for barbiturates (Evans and Keogh, 1977; Whitwam, 1978) . Although adverse responses to Althesin may follow a first or subsequent exposure, the relative frequency of reactions in these two situations is unknown. Since it is unlikely that both reactions are mediated in the same way, we have investigated 30 cases of apparent hypersensitivity to Althesin for possible immunological involvement and report the clinical and laboratory findings.
The clinical signs are those typical of an anaphylactic reaction produced by generalized histamine release which may occur immunologically either by IgE-mediated immediate hypersensitivity not involving complement, or by activation of the complement cascade. Two separate pathways exist for complement activation: the classical pathway, initiated by an antigen-antibody interaction in which the antibody involved is IgG or IgM, and the alternative pathway in which no antibody is involved. Both IgE-and classical pathway-mediated hypersensitivity responses are dependent upon previous exposure to the antigen. Various conflicting reports have suggested that Althesin reactions in- volve either IgE (Watkins, 1979; Fisher, 1980) , classical (Watkins, Allen and Milford Ward, 1978) or alternative complement pathway activation (Watkins, Clarke et al., 1976; Watkins, Udnoon et al., 1976) . A direct non-imrnunologically-mediated effect of the drug on mast cells, releasing histamine, has also been suggested (Watkins, Clark et al., 1976; Watkins, 1979) .
METHODS

Clinical observations
The 30 patients reported represent the total number referred to us in whom Althesin alone could be held responsible for their hypersensitivity reactions. A number of other patients to whom Althesin was administered simultaneously with another drug known to cause hypersensitivity, for example alcuronium chloride (Fisher, Hallowes and Wilson, 1978) , have been excluded. Clinical signs of hypersensitivity varied widely (table I) , although no reaction was fatal. The severity of the response was assessed clinically by the degree of cardiovascular collapse, a severe reaction being classified as one in which the systolic arterial pressure decreased to less than 60 mm Hg in conjunction with other symptoms of anaphylaxis.
In every patient, following resuscitative treatment, anaesthesia and surgery proceeded uneventfully. The medical histories of the patients were re-examined and none in this study was found to have any known immunological or haematological disease. Patient 22, however, was undergoing radiotherapy for uterine cervical neoplasm, and pa- 
Blood samples
Sequential samples of venous blood were collected into specially prepared bottles containing di-potassium ethylene diamine tetracetic acid (EDTA) 1 mgml" 1 at the time of reaction and at increasing intervals over the next 24 h. The plasma from these samples was separated as quickly as possible and deep frozen if analysis was not to be performed immediately. Two-dimensional immunoelectrophoresis was i used to identify the breakdown products of the C3 complement component, based upon a modification (Versey, 1973) The results of the 17 patients who had previously been exposed to Althesin are shown in table III. C3 conversion occurred in every case. Of the 14 in whom C4 was measured, 12 showed marked C4 consumption ranging from 18% to 93%, while in two the concentrations were unchanged. The dilutional effect of i.v. fluid therapy was considered in relation to C4 reduction, but was felt unlikely to be responsible for changes of this magnitude. In contrast to the patients reacting on first exposure to the drug, nine of the 17 re-exposed patients suffered a severe rlinir-al reaction.
Cl esterase inhibitor concentrations were measured in all patients to exclude anyone with preexisting reduced concentrations characteristic of hereditary angioneurotic oedema. The apparently large concentrations found in some patients, while having no bearing on the immune reaction, probably reflect tissue trauma which inevitably produces increased concentrations of this acute phase protein.
DISCUSSION
The complement system is a series of nine plasma proteins, activated as a cascade the ultimate effect of which is to produce cell lysis ( fig. 3) . Classical activation of this system following a type II or III hypersensitivity reaction as described by Gell, Coombs and T.arhmnnn (1975) involves the Cl, 4,2 sequence. In the alternative pathway, C3 conversion may be initiated by a number of substances such as bacterial polysaccharides, virally infected cells and various toxins. This activation does not involve antibody and therefore docs not require previous sensitization. While C3 activation is common to both classical and alternative pathways, C4 is involved only in the classical pathway. Histamine release following activation of the complement cascade is produced by the action of anaphylatoxins (C3a and C5a) on mast cells. The final common pathway of both routes of activation is C5-9.
In contrast to previous reports (Watkins, Allen and Milford Ward, 1978; Watkins, 1979; Fisher, 1980) which suggest various mechanisms responsible for hypersensitivity reactions to Althesin, our results demonstrate a distinct difference in complement involvement between those patients reacting on first exposure and those who have been previously sensitized to the drug. Isolated conversion of the C3 complement component, as seen in all of the five immunologically-mediated first time reactors (table II) implies that hypersensitivity has occurred by direct activation of the alternative pathway. It is not clear which mechanism was responsible in the eight remaining first-time reactors in whom no immunological involvement was seen. The involvement of both C3 and C4 observed in the patients reacting on re-exposure to Althesin is diagnostic of classical complement pathway activation typically occurring following a Type II or III hypersensitivity reaction (Gell, Coombs and Lachmann, 1975) and implies immune recognition.
The consistent activation of the classical complement pathway in all our patients reacting on reexposure to Althesin would not have occurred if the antibody involved was IgE, because IgE does not bind complement. The role of IgE-mediated hypersensitivity in Althesin reactions has been described by Fisher (1980) , who claimed that the majority of his patients show a positive response to intradennal skin testing following adverse reactions.
Since our results show that reactions following re-exposure to Althesin mimic Type II or III hypersensitivity reactions, the recommendation (Dinmore, 1979) that patients should be given an i.v. test dose must be viewed with extreme caution. Minute quantities of antigen are sufficient to precipitate anaphylaxis in a previously sensitized patient. Furthermore, we would not agree with the suggestion (Dinmore, 1979) that reactions on first exposure to Althesin are dose-related in intensity. One of our patients (No. 10) reacted on first exposure to a 0.5-ml test dose of the drug.
In conclusion, we believe that confirmation of a true hypersensitivity reaction to Althesin requires not only a clinical history of anaphylaxis, but also immunological evidence of complement activation. A distinct difference exists between the immunological mechanisms involved in reactions following first and subsequent exposure to Althesin. We believe that the frequency of severe reaction would be considerably reduced by avoiding re-exposure to the drug. Se investigo muestras secuenciales de plasma de 30 pacientes que daban senates dinicas de hipersensibilidad a la alteaina con el objeto de determinar si existia una respuesta etpecifica de inmumdad a dicha substancia (medida por la activaci6n daska de la senda del complemento) o si ocurria una activaci6n de la senda del complemento alternativa nodependiente de los anticuerpos. Se repartieron a los pacientes en dos clases: los que tuvieron una reaccion despues de la primers exposition a la altesina y los que reaccionaron de manera ad versa solamente despues de la segunda exposid6n. En cinco de los que reaccionaron a la prim era exposicion (13), se activo la senda del complemento alternative, mas no se activo a la senda clasica, mientras que en los ultimos ocho pacientes, no se observo alguna activacion del complemento. En contraste, se observo una activacion de la senda del complemento clasico en las muestras de sangre de todos los 17 pacientes cuya reacci6n se produjo despues de una exposicion reiterada. Tuvieron lugar severas reacciones en nueve de los 17 pacientes previamente expuestos en comparacion con uno solo entre los 13 pacientes que reaccionaron despues de la primers exposicion a la altesina. Downloaded from https://academic.oup.com/bja/article-abstract/54/8/859/248829 by guest on 19 March 2019
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